Infex Therapeutics has filed for a UK patent for a novel therapy designed to tackle all coronavirus strains. The COV-X program targets a protein which is essential for viral replication across a broad spectrum of related coronaviruses, including SARS-CoV-1, MERS-CoV and SARS-CoV-2.
If successfully developed, the treatment aims to form a first line of defence against potential future pandemics. It could be administered as a precautionary measure to vulnerable groups including the elderly, immunocompromised people, and healthcare workers, greatly reducing the health risks and buying time to allow a bespoke vaccine to be produced.
Dr Peter Jackson, Executive Director of Infex Therapeutics, said: “We all hope the COVID-19 pandemic is approaching its end, but it’s crucial we don’t lose sight of what could, and sadly inevitably will, come next. […] Establishing the effectiveness of a novel and differentiated series of compounds early will be crucial, and we look forward to exploiting the opportunities this patent presents in order to help protect lives and economies across the world whenever the next coronavirus pandemic arrives.”
Recent research has shown that the structures of key essential proteins are consistent across different coronavirus types, giving the potential to develop new therapeutics with broad spectrum activity across related pathogens with the potential for futureproofing against outbreaks and pandemics.
Infex Therapeutics is now embarking on a fast-track development program for the COV-X project, to take these promising research results forward into clinical trials.The program is backed by the Hits-to-Leads program within iiCON, the infectious disease innovation consortium led by the Liverpool School of Tropical Medicine and supported by the Strength in Places Fund.